Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin versus doxorubicin + trabectedin followed by trabectedin in first-line metastatic or unresectable leiomyosarcoma
2016-002186-56Phase 3Active
- Sponsor
- Gustave Roussy
- Start
- Oct 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in leiomyosarcoma (LMS) and uterine leiomyosarcoma (uLMS) comparing Doxorubicin alone with Doxorubicin + trabectedin followed by trabectedin (2 arms). Primary endpoint: Progression-free survival. Started Oct 2016; status: active.
02
Drugs
doxorubicintrabectedin
03
Conditions
leiomyosarcoma (LMS)uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on 2016-002186-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002186-56.